Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.
In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, research led by Memorial Sloan Kettering Cancer Center ...
Indiana cities and counties have received over $110 million from a landmark settlement with national opioid distributors to help fund drug treatment and prevention efforts.
In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells ...
In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...
A total of 118 recommendations based on expert consensus were published regarding the treatment of hidradenitis suppurativa ...
Deep Track, a Greenwich, Ct., investment management company that holds 13.5% of Dynavax's stock, pointed its finger at ...
The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.
Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...
University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood – ...
A new study in the Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic acid-inducible gene I ...
Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback